P=N/A, N=8, Enrolling by invitation, Institute of Hematology & Blood Diseases Hospital, China

P4, N=158, Completed, Chong Kun Dang Pharmaceutical | Recruiting --> Completed

P4, N=150, Completed, Chong Kun Dang Pharmaceutical | Recruiting --> Completed

P3, N=65, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients

Mycophenolate mofetil was discontinued, and tacrolimus levels were maintained at 6-8 ng/mL...EBV-negative PTLD is rare and often fatal. Ascitic fluid cytology can facilitate early, minimally invasive diagnosis, warranting high clinical suspicion in transplant recipients with unexplained ascites.

P1, N=1, Active, not recruiting, Xijing Hospital

Isolated APS may represent an important yet under-recognized manifestation of post-COVID-19 autoimmune neuroinflammation. Detection of SARS-CoV-2 in CSF supports a role for direct viral neuroinvasion as a localized inflammatory stimulus. AQP4-IgG serostatus serves as a critical prognostic determinant: seronegativity is associated with a benign, monophasic course, whereas seropositivity mandates prompt initiation of potent immunosuppressive therapy to prevent devastating relapses. Clinicians should maintain a high index of suspicion for NMOSD in patients with unexplained persistent vomiting following COVID-19, and perform urgent neuroimaging and antibody testing for early risk stratification.

P4, N=14, Active, not recruiting, University of California, Davis | Recruiting --> Active, not recruiting | N=50 --> 14 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

These findings collectively indicate that compound 5k exerts synergistic anti-CRC efficacy by triggering ferroptosis and activating antitumor immunity. Thus, compound 5k holds considerable promise as a lead ferroptosis inducer for the development of novel CRC therapeutic strategies.

P=N/A, N=96, Not yet recruiting, Assiut University

The patient was managed with corticosteroids, mycophenolate mofetil (MMF), and intravenous immunoglobulin G (IVIG), but later developed supraventricular tachycardia and deep vein thrombosis. This report emphasizes the need to enhance recognition of immune-related toxicities within non-oncology specialties to support prompt interdisciplinary collaboration and appropriate patient management. Additionally, patients can develop myocarditis-related complications even when clinically stable or near the end of treatment, underscoring the need for close and ongoing monitoring.

P=N/A, N=224, Recruiting, The First Affiliated Hospital of Soochow University